These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 24620626)

  • 61. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.
    Pimentel M; Park S; Mirocha J; Kane SV; Kong Y
    Ann Intern Med; 2006 Oct; 145(8):557-63. PubMed ID: 17043337
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
    Kasir R; Zakko S; Zakko P; Adler M; Lee A; Dhingra S; Guttermuth C
    Dig Dis Sci; 2016 Mar; 61(3):846-51. PubMed ID: 26362282
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of gut microflora and probiotic effects in the irritable bowel syndrome.
    Fanigliulo L; Comparato G; Aragona G; Cavallaro L; Iori V; Maino M; Cavestro GM; Soliani P; Sianesi M; Franzè A; Di Mario F
    Acta Biomed; 2006 Aug; 77(2):85-9. PubMed ID: 17172187
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.
    Leventogiannis K; Gkolfakis P; Spithakis G; Tsatali A; Pistiki A; Sioulas A; Giamarellos-Bourboulis EJ; Triantafyllou K
    Probiotics Antimicrob Proteins; 2019 Jun; 11(2):627-634. PubMed ID: 29508268
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.
    Lupascu A; Gabrielli M; Lauritano EC; Scarpellini E; Santoliquido A; Cammarota G; Flore R; Tondi P; Pola P; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1157-60. PubMed ID: 16305730
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Restless legs syndrome is associated with irritable bowel syndrome and small intestinal bacterial overgrowth.
    Weinstock LB; Walters AS
    Sleep Med; 2011 Jun; 12(6):610-3. PubMed ID: 21570907
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Obesity Is Inversely Related to Hydrogen-Producing Small Intestinal Bacterial Overgrowth in Non-Constipation Irritable Bowel Syndrome.
    Jung SE; Joo NS; Han KS; Kim KN
    J Korean Med Sci; 2017 Jun; 32(6):948-953. PubMed ID: 28480652
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors.
    Sachdeva S; Rawat AK; Reddy RS; Puri AS
    J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():135-8. PubMed ID: 21443727
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Small intestinal bacterial overgrowth as an uncommon cause of false positive lactose hydrogen breath test among patients with diarrhea-predominant irritable bowel syndrome in Asia.
    Wang Y; Xiong L; Gong X; Li W; Zhang X; Chen M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):995-1000. PubMed ID: 25470082
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective.
    Spiegel BM
    Clin Gastroenterol Hepatol; 2011 Jun; 9(6):461-9; quiz e59. PubMed ID: 21397724
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antibiotics for irritable bowel syndrome: rationale and current evidence.
    Sachdev AH; Pimentel M
    Curr Gastroenterol Rep; 2012 Oct; 14(5):439-45. PubMed ID: 22945316
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
    Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
    Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.
    Furnari M; De Alessandri A; Cresta F; Haupt M; Bassi M; Calvi A; Haupt R; Bodini G; Ahmed I; Bagnasco F; Giannini EG; Casciaro R
    J Gastroenterol; 2019 Mar; 54(3):261-270. PubMed ID: 30232597
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies.
    Shah A; Talley NJ; Jones M; Kendall BJ; Koloski N; Walker MM; Morrison M; Holtmann GJ
    Am J Gastroenterol; 2020 Feb; 115(2):190-201. PubMed ID: 31913194
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases].
    Madrid AM; Defilippi C C; Defilippi G C; Slimming A J; Quera P R
    Rev Med Chil; 2007 Oct; 135(10):1245-52. PubMed ID: 18180830
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?
    Reddymasu SC; Sostarich S; McCallum RW
    BMC Gastroenterol; 2010 Feb; 10():23. PubMed ID: 20175924
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Does Carbohydrate Challenge Testing Predict Clinical Response in Small Intestinal Bacterial Overgrowth?
    Long SK; Di Palma JA
    South Med J; 2016 May; 109(5):296-9. PubMed ID: 27135726
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.
    Ghoshal UC; Srivastava D
    World J Gastroenterol; 2014 Mar; 20(10):2482-91. PubMed ID: 24627585
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin.
    Weinstock LB; Steinhoff M
    J Am Acad Dermatol; 2013 May; 68(5):875-6. PubMed ID: 23602178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.